Du är här

2014-05-23

Omnicare: Omnicare Makes Donation to the Neurodegeneration Consortium to Advance the Study and Treatment of Alzheimer's

CINCINNATI, May 23, 2014
- Omnicare, Inc. (NYSE: OCR) today announced a $50,000 donation to the
Neurodegeneration Consortium (NDC), a collaboration of The University of
Texas MD Anderson Cancer Center, Baylor College of Medicine and the
Massachusetts Institute of Technology. The NDC is a transformative initiative
to advance the study and treatment of Alzheimer's and other neurodegenerative
diseases.

"Our organization plays a critical role in improving the quality of care for
those afflicted with neurodegenerative diseases," said Nitin Sahney,
Omnicare's President and Chief Operating Officer. "We are pleased to have the
opportunity to partner with this initiative whose work is parallel to our
services and core values, and to contribute to the community in a meaningful
way."

The NDC's mission is to identify key molecular targets that cause Alzheimer's
and other neurodegerative diseases and to rapidly translate these discoveries
into treatments. Recent research has revealed common molecular themes in
neurodegeneration, cancer and other age-associated diseases.

"We are deeply grateful to Omnicare for supporting the NDC's efforts to
understand and overcome one of the greatest challenges facing humanity in
this century," said Ron DePinho, M.D., president of MD Anderson. "Our aim is
to find out how and why neurodegenerative diseases develop and to find the
key steps to prevent or slow disease progression, while addressing quality of
life issues and the financial challenges of living with Alzheimer's disease,
Parkinson's disease and chemotherapy induced neuropathy. Philanthropy is the
driving force behind this initiative, and Omnicare's generous gift of $50,000
is a much-needed boost to the NDC and its unique approach."

The donation is funded by the Omnicare Foundation, a nonprofit whose mission
is to improve health and to support organizations that make a positive
difference in the lives of individuals in the communities that we serve.

About Omnicare

Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across the
United States. As the market-leader in professional pharmacy, related
consulting and data management services for skilled nursing, assisted living
and other chronic care institutions, Omnicare leverages its unparalleled
clinical insight into the geriatric market along with some of the industry's
most innovative technological capabilities to the benefit of its long-term
care customers. Omnicare also provides key commercialization services for
the bio-pharmaceutical industry through its Specialty Care Group. For more
information, visitwww.omnicare.com.

About MD Anderson

The University of Texas MD Anderson Cancer Centerin Houston ranks as one of
the world's most respected centers focused on cancer patient care, research,
education and prevention. MD Anderson is one of only 41 comprehensive cancer
centers designated by the National Cancer Institute. For 10 of the past 12
years, including 2013, MD Anderson has ranked No. 1 in cancer care in "Best
Hospitals," a survey published annually inU.S. News&World Report. MD Anderson
receives a cancer center support grant from the National Cancer Institute of
the National Institutes of Health (P30 CA016672).

# # #

Contacts:
Omnicare
Patrick C. Lee
(513) 719-1507
patrick.lee@omnicare.com

MD Anderson
Sarah Watson
(713) 745-6109
swatson@mdanderson.org

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire

HUG#1787720

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.